Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer. Their study, published in Molecular Cancer Research, is the first to link the enzyme PRSS3 to prostate cancer. Read more here.
Study mentioned: Hockla A, et al. Angiogenesis, Metastasis, and the Cellular Microenvironment PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer. Mol Cancer Res. December 2012;10:1555-1566.
No comments:
Post a Comment